Universal Detection Technology signs new distribution agreement for bioterrorism technologies

Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that has signed a distribution agreement with Strategic Response Initiatives, a New York based defense firm specializing in all phases of emergency preparedness planning for a wide range of defense, public and private sector organizations.

Under the new agreement, Strategic Response Initiatives will market and distribute Universal Detection Technology’s Bio-Weapons Detection Systems to a wide range of accounts, including the Department of Homeland Security, Department of Defense, New York and New Jersey state governments and various private defense contractors. SRI will also be submitting Universal Detection Technology’s equipment to the Guardian Installation Protection Program and to Hazardous Incident Response Equipment.

“Our partnership with Strategic Response Initiatives proves that Universal Detection Technology is committed to bringing the latest technology in early detection bioterrorism monitoring to those government, public and private organizations at the forefront of emergency preparedness and response,” said Jacques Tizabi, CEO of Universal Detection Technology. “SRI’s specific expertise in weapons of mass destruction is a major component to our working relationship.”

SRI’s customers include Department of Homeland Security, US State Department, US Marine Corps Chemical Biological Incident Response Force (CBIRF) and NATO forces in Afghanistan.

Available biodetection technology to SRI customers will be Universal Detection Technology’s five agent handheld biodetection kits, which recently received certification by the Department of Homeland Security.

“Strategic Response Initiative’s partnership with Universal Detection Technology is bringing the latest state-of-the-art bioterrorism technology to the defense contract market,” said SRI founder and CEO Robert L. Domenici, a retired U.S. Army lieutenant colonel. “This kind of technology is critical to the advancing complexities of first responders, defense and counter-terrorism.”

For more information, please visit www.udetection.com or email [email protected].

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, Universal Detection Technology, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products. www.udetection.com.

About Strategic Response Initiatives (SRI)

Strategic Response Initiatives, LLC (SRI) was initially organized in November of 2005 as a Limited Liability Corporation providing procurement and domestic disaster preparedness training services. As a logical outgrowth of these activities, SRI now assists and supplies various military, firefighting, police, emergency medical services (EMS) and other First Responder organizations worldwide, with their critical equipment, equipment support, equipment specific training, tactical training and information technology needs.

SRI is seeking to become the leading integrator of proven and emerging technologies in the area of specialized logistics management, security assistance and training as well as environmental and disaster preparedness equipment systems and training for military, government and corporate use.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024